CDA Diefenbach Medpace Protocol ID ME-522-001 titled: A Phase 1 Open-label Study of Voruciclib in Subjects with Relapsed and/or Refractory B Cell Malignancies After Failure of Prior Standard Therapies

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Relapsed And/or Refractory B Cell Malignancies
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Histologically-confirmed diagnosis of follicular lymphoma (FL),mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), chronic lymphocytic lymphoma (CLL), or diffuse large B-cell lymphoma (DLBCL) 2. Patients must have disease that has relapsed or is refractory to 2 or more prior regimens and in need of treatment due to progressive disease 3. Patients must have received all appropriate standard therapy for the patient’s malignancy and have developed disease progression or are intolerant to appropriate standard therapy

You may not be eligible for this study if the following are true:

  • 1. Known histological transformation to an aggressive lymphoma (e.g., Richter transformation) 2. Known central nervous system involvement 3. History of another malignancy


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.